


2016 ANNUAL GENERAL MEETING



ARKEMA
INNOVATIVE CHEMISTRY



**10 years after,
a completely different profile**

ARKEMA
INNOVATIVE CHEMISTRY

A real step change in safety and sustainable development



TRIR *



1.5 versus 11.3 in 2005



Greenhouse gas emissions



-64% versus 2005



Volatile organic compound emissions




-43% versus 2005


2015 achievements

* Total recordable injury rate per million of hours worked

Better balanced geographical footprint



A portfolio refocused on specialties



Stronger financials

SALES



+2 billions of euros
compared to 2005

EBITDA



x3
versus 2005

EBITDA MARGIN



13.8%
versus 6.2% in 2005

NET DEBT



<40% of shareholders' equity
stable versus 2005

2015 achievements

Strong value creation for shareholders




 Market capitalization multiplied by 3

Dividend: a key element of shareholders' return

Dividend and payout ratio


in € / share and in %




Dividend policy:
« Aims to pay a stable to growing dividend each year »

* Dividend proposed to this Annual General Meeting

Transformative acquisitions





2015 highlights

Arkema in 2015



€**7.7** bn
sales



19,000
employees
worldwide



Worldwide
presence in
50 countries




136
industrial sites



3 R&D
and innovation
geographical hubs



A strong set of results



2015 highlights

BOSTIK



Successful integration

THIOCHEMICALS



Technical and commercial success

DIVESTMENT PROGRAM



Divestment of Sunclear

FLUOROGASES



Gradual improvement of profitability

SUNKE



Recent developments in contractual terms

ARKEMA RECOGNIZED



Innovation, CSR and sustainable development

Bostik: a successful integration




New Bostik unit in the Philippines

- ✦ 2015 EBITDA up 16% versus 2014
- ✦ Smooth and quick integration
- ✦ Synergies well on track with first benefits already achieved in 2015
- ✦ 11.2% EBITDA margin in 2015 (10.3% in 2014)
- ✦ New production units:

🏭 Malaysia 🏭 Philippines 🏭 Monterrey (Mexico) 🏭 Dallas (United States) 🏭 Bangalore (India)

* of which 11 months within Arkema



Bostik: close to consumer

Making the Bostik brand fly across Europe



and ride along with the Tour de France



Bostik: close to professionals



The Smart House

Thiochemicals in Malaysia



Arkema's largest industrial project since its stock market listing

Start-up of the unit in 1st quarter of 2015

Technological and commercial success

Ramp-up quicker than anticipated supported by the animal nutrition market in Asia

Acrylics in China: recent developments



Sunke

- ✦ Acrylic acid production joint-venture
- ✦ Arkema has a right to 160 kt production capacities of acrylic acid per year
- ✦ Early 2016, Arkema decided not to exercise its €200 M option to double its rights to production capacities

Ongoing discussions with the partner

- ✦ Access an additional 80 kt acrylic acid production capacities per year
- ✦ Limited cash-out of around €40 M

Possibility to invest the amounts freed-up in the High Performance Materials division

2015: an award-winning year



Quality of regulated information
Grand Prix in the category
« Oil, Gas, Materials and Buildings »



AGEFI
Second prize in
Dynamique de gouvernance



Thomson Reuters
5th year in a row in the
top 100 most innovative companies in the world




Carbon Disclosure Project
« Improvement Award – France »



EcoVadis
Gold level corresponding to the
highest CSR performance level



FTSE4Good
Entry in the index



Innovation at the heart of the strategy

ARKEMA
INNOVATIVE CHEMISTRY

3 geographic R&D hubs

United States


 450 researchers

France

 1,000 researchers

Asia (China, Japan, South Korea)

 150 researchers



A R&D dedicated to customers

Tomorrow's materials, a major innovation area for Arkema

<p>PEKK « The polymer of the extreme »</p>	<p>Rilsan® High Temperature</p>	<p>Elium®</p>
		
<p>COMPOSITES</p>	<p>AUTOMOTIVE AND TRANSPORTATION</p>	<p>NEW ENERGIES</p>

Tomorrow's materials, a major innovation area for Arkema

KYNAR® MEMBRANES



WATER TREATMENT

PEBAX® RNEW




SPORT

STRUCTURAL ADHESIVES



ASSEMBLY OF ALL MATERIALS

A R&D focused on 6 platforms



Latest developments in R&D

**VENETTE
(France)**



**DEVELOP
TOMORROW'S ADHESIVES**

**CHANGSHU
(China)**




**ACCELERATE THE
DEVELOPMENT OF LOCAL
SOLUTIONS**

**SEOUL TECHNICAL CENTER
(South Korea)**



**OPENING OF A LABORATORY
WITHIN
HANYANG UNIVERSITY**



2020 ambition

Long-term priorities

HIGH PERFORMANCE MATERIALS

Accelerate the growth of the division

GEOGRAPHICAL PRESENCE

Finalize the rebalancing while reinforcing the presence in emerging countries

BOSTIK

Achieve our ambitions in adhesives notably through acquisitions

INNOVATION

Major trends in sustainable development notably in composites

COATING SOLUTIONS



Pursue the development of the acrylics downstream

SAFETY / CSR

Go one step further in safety and CSR


A strong CSR ambition

2025 targets



(1) Relative indicators based on 2012 reference year

(2) The Arkema Integrated Management System (AIMS) combines ISO 9001, ISO 14001, and OHSAS 18001 requirements



2015 financial results

2015 key figures

+29%

Sales
7.7 billion euros

+35%

EBITDA
1,057 million euros

13.8%

EBITDA margin
versus 13.2% in 2014

+27%

Adjusted net income
312 million euros


+71%

Net income Group share
285 million euros

+14%

Adjusted net income per share
4.23 euros

Sales bridge



2014

2015

Performance by division

IN €M	2014*	2015	Variation
Sales	1,730	3,358	+94.1%
EBITDA	314	506	+61.1%
EBITDA margin	18.2%	15.1%	Bostik dilutive impact

IN €M	2014*	2015	Variation
Sales	2,269	2,450	+8.0%
EBITDA	312	418	+34.0%
EBITDA margin	13.8%	17.1%	

IN €M	2014*	2015	Variation
Sales	1,930	1,849	(4.2)%
EBITDA	203	190	(6.4)%
EBITDA margin	10.5%	10.3%	

HIGH PERFORMANCE MATERIALS

Successful integration of Bostik and innovation in lightweight materials and new energies

INDUSTRIAL SPECIALTIES


Very good performance driven by all product lines

COATING SOLUTIONS

Good resilience of the division thanks to the downstream integration

* Restated figures in accordance with the new reporting structure presented in June 2015

Strong cash generation





High EBITDA to cash conversion ratio
at 42%

Good control of capital expenditure
and working capital

Positive impact of lower costs of some
raw materials

(1) Cash flow from operations and investments excluding the impact of portfolio management

Capturing growth while reducing capital intensity




Capital intensity
Capex / sales in %

(1) Excluding capex related to M&A (mainly related to the transfer of a 3rd acrylic production line to Sunke without any impact on net debt)

Net debt

Net debt in €M
excluding €700 M hybrid bond



Net debt decreased quicker than anticipated since Bostik acquisition in 1Q'15

Net debt / EBITDA: 1.3x

Net debt / shareholders' equity: 35%

Average debt maturity > 5 years

1Q'16 key figures

+1.2%

Sales
1.9 billion euros

+27%

EBITDA
302 million euros

16.0%

EBITDA margin
versus 12.7% in 1Q'15

HIGH PERFORMANCE MATERIALS

- ✦ **€149 M EBITDA** up 34 % YoY
- ✦ Bostik contribution and developments in Technical Polymers
- ✦ **EBITDA margin** of 17.2 %

INDUSTRIAL SPECIALTIES

- ✦ **€129 M EBITDA** up 39 % YoY
- ✦ Higher performance for each Business Line
- ✦ **EBITDA margin** of 22.0 %

COATING SOLUTIONS

- ✦ **€50 M EBITDA** down 6 % YoY
- ✦ Good resilience thanks to a solid downstream integration
- ✦ **EBITDA margin** of 11.6 %

2016 outlook confirmed

A world economy remaining slow and volatile:


- ✦ Overall moderate global growth with low visibility and different dynamics by region
- ✦ Volatility in currencies, energy and raw material prices

Strong organic momentum driven by:

- ✦ Continuous development of Bostik including ramp-up of synergies
- ✦ Progressive improvement of fluorogases business (pricing and competitiveness)
- ✦ In Thiochemicals, additional contribution of the Malaysian platform expected in 2016 vs 2015 already fully booked in 1Q'16. Performance of remaining 9 months of 2016 expected to be comparable to that of last year
- ✦ Operational excellence initiatives to offset part of the inflation on fixed costs
- ✦ Benefit from innovation in lightweight materials and sustainable solutions



Based on these drivers and assuming an environment in line with the start of the year as regards energy and currencies,
Arkema reiterates its confidence in its ability to grow EBITDA in 2016



Governance

Board of Directors



Thierry **Le Hénaff**




Claire **Pedini**



Laurent **Mignon**



Isabelle **Boccon-Gibod**



Bernard **Kasriel**



Marc **Pandraud**



Victoire **de Margerie**



François **Enaud**



Thierry **Morin**



Patrice **Bréant**



Philippe **Vassor**



Hélène **Moreau-Leroy**

12
MEMBERS

4
WOMEN

1
DIRECTOR REPRESENTING
SHAREHOLDER EMPLOYEES

82%
INDEPENDENCE RATE

✦ Appointment of a director representing employees as from 2016, subject to the approval of the **19th resolution**

Activity of the Board and Committees in 2015

BOARD OF DIRECTORS



6 meetings
93% attendance rate



1 annual seminar of the Board dedicated to the Group's strategy
100% attendance rate

SPECIALIZED COMMITTEES

AUDIT AND ACCOUNT COMMITTEE



6 meetings
100% attendance rate

NOMINATING, COMPENSATION AND CORPORATE GOVERNANCE COMMITTEE



4 meetings
100% attendance rate

Board of Directors' assessment

PRINCIPLES

- ✦ Assessment conducted early 2016 by an external consultant on the basis of individual interviews of each director

STRENGTHS

- ✦ Functioning of the Board assessed as very good
- ✦ Current governance structure with a combined role of Chairman and CEO fully adapted
- ✦ Further implementation of corporate governance best practices
- ✦ Board's debates allow for an open expression of opinions and an informed support for the most important decisions
- ✦ Strong involvement of the Board on the strategy

AREAS TO REINFORCE

- ✦ Continue to benefit from the experience of an executive in the chemical sector
- ✦ Maintain the proportion of active CEO directors
- ✦ Develop internationalization
- ✦ Reinforce periodic field visits and possibly organize a Board of Directors' meeting on site

Re-election of Thierry Le Hénaff as director (6th resolution)

**Combination of the positions of Chairman and Chief Executive Officer:
A simple, fast and efficient decision-making process that has proved its
efficiency since the Company's stock market listing**

- ✓ Proven efficiency of the Board' functioning since 10 years
- ✓ Very positive achievements of Thierry Le Hénaff
- ✓ Very large majority of independent directors on the Board and the Committees
- ✓ Unanimity of the directors on the relevance of the corporate governance structure with combined positions of Chairman and CEO
- ✓ Clear and appropriate limitations of the power of the Chairman and CEO

Appointment of a Senior Independent Director

Part of the drive to constantly improve the Company's governance

- ✦ Decision in line with corporate governance best practice
- ✦ Mandatory when the Chairman of the Board of Directors also serves as Chief Executive Officer

Role and responsibilities described in detail in the Board of Directors' Internal Rules

- ✦ Oversee the efficient running of the Company's governance structure
- ✦ Take part in the prevention and management of conflicts of interests
- ✦ Ensure the shareholders' concerns on corporate governance matters are taken into consideration


Appointment to this role in March 2016 of François Enaud, independent director and member of the Nominating, Compensation and Corporate Governance Committee since 2006

Compensation of the Chairman and Chief Executive Officer

Structure of the compensation in 2015

LONG-TERM COMPENSATION: PERFORMANCE SHARES

Vesting subject to
3 challenging criteria



SHORT-TERM COMPENSATION: VARIABLE PART


- ✦ 3 quantitative criteria
- ✦ ~15 indicators for the qualitative criteria

FIXED COMPENSATION



3/4 of the compensation linked to the Company's performance over the short and long-term

Variable part structure



Components of compensation submitted to the advisory vote of the shareholders (7th resolution)

<i>(in euros)</i>	Amount	Description
Fixed compensation	750,000	<ul style="list-style-type: none"> ✦ Unchanged since May 2012 ✦ Increased to €900,000 from the renewal of his term of office
Annual variable compensation	1,125,000	<ul style="list-style-type: none"> ✦ Reflects the excellent performance in 2015 ✦ Quantitative criteria: 73% of the variable part ✦ Qualitative criteria: 27% of the variable part ✦ Overall achievement rate: 100% <ul style="list-style-type: none"> • 100% for each of the 3 quantitative criteria • 100% for the qualitative criteria ✦ Structure unchanged for 2016
Performance shares	26,000 rights	<ul style="list-style-type: none"> ✦ 100% subject to performance criteria ✦ Same amount of rights granted since 2012

Other agreements concerning the Chairman and Chief Executive Officer

Termination indemnity (5th resolution)

- ✦ Indemnity in the event of forced departure in compliance with the recommendations of the AFEP-MEDEF Code
- ✦ Maximum of **2 years** of fixed and variable compensation
- ✦ Fully subject to **5 demanding performance conditions**
- ✦ Performance conditions significantly reinforced since this agreement was first approved by Shareholders meeting in 2006

Pension scheme

- ✦ **Termination** of the supplementary defined benefit pension scheme of the Chairman and Chief Executive Officer
- ✦ Replacement by a new scheme with:
 - an additional annual compensation to enable him to build up his supplementary retirement benefits
 - a one-off lump sum in cash and shares to compensate for the loss of part of the rights accumulated in the terminated scheme
- ✦ New scheme represents a **strong reduction of what the beneficiary would have been entitled to** and significant **cost savings for the Company with a cost divided by two**
 - Reversal of a provision amounting to 20 million euros in the financial accounts at end of June 2016
- ✦ Authorization to carry out the one-off grant in shares submitted in the **18th resolution**

Performance shares (17th resolution)

Renewal of the authorization granted by the Annual General Meeting in 2013

Objective is to involve more closely members of the executive management and certain employees to the Group's future growth and stock market performance

- ✦ Around 1,100 beneficiaries following Bostik integration early 2015
- ✦ Aligns interests of the beneficiaries with those of shareholders

A practice constantly reinforced since 2013

- ✦ Introduction of a criterion related to the return to shareholders (TSR) and of a criterion of cash generation
- ✦ Maximum percentage of rights that can be awarded to the Chairman and Chief Executive Officer limited to 10% of the annual performance share plan
- ✦ Vesting after 3 years followed by a lock-up period of 2 years
- ✦ Better reward of the outperformance introduced in 2015

2015 plan subject to 3 demanding criteria: EBITDA growth, EBITDA to cash conversion rate and comparative Total Shareholder Return

Grant of existing shares thus avoiding any dilution for shareholders

Success of the share capital increase reserved for employees

2016 share capital increase reserved for employees

40% average participation rate and **67%** in France

26 countries across the world

998,072 shares subscribed

€42 M invested

More than 6% of the share capital held by Group's employees



Strong involvement of the employees in
the Group's development and performance

Renewal of the delegation of authority submitted in the 16th resolution

Disclaimer

The information disclosed in this document may contain forward-looking statements with respect to the financial condition, results of operations, business and strategy of Arkema. Such statements are based on management's current views and assumptions that could ultimately prove inaccurate and are subject to material risk factors such as among others, changes in raw material prices, currency fluctuations, implementation pace of cost-reduction projects and changes in general economic and business conditions. These risk factors are further developed in the reference document.

Arkema does not assume any liability to update such forward-looking statements whether as a result of any new information or any unexpected event or otherwise. Further information on factors which could affect Arkema's financial results is provided in the documents filed with the French Autorité des marchés financiers.

Financial information for 2016, 2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006 and 2005 is extracted from the consolidated financial statements of Arkema. Quarterly financial information is not audited.

The business segment information is presented in accordance with Arkema's internal reporting system used by the management.

The definition of the main performance indicators used can be found in the press release on the quarterly results.